What is the definition of Gliosarcoma?

Gliosarcoma is a rare type of brain tumor that develops from glial cells, which are specialized cells that surround and support neurons (nerve cells). Unlike gliomas, gliosarcomas have a higher likelihood to spread to the lymph nodes, lungs, and liver. 

What are the causes for Gliosarcoma?

The cause of gliosarcomas is still unknown. However, gliosarcomas generally tend to be more common in adults than children. Men are also more likely to develop gliosarcomas than women.

What are the symptoms for Gliosarcoma?

The symptoms of gliosarcomas primarily depend on the tumor's location as well as how much the tumor has spread. Common symptoms include headaches, memory difficulties, fatigue, numbness, balance issues, and seizures. 

What are the current treatments for Gliosarcoma?

Treatment for gliosarcoma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove as much of the tumor as possible is generally the first step in treating gliosarcoma. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of gliosarcoma. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.

How do I prevent Gliosarcoma?

There is no known way to prevent gliosarcomas. However, if you develop any symptoms common to a gliosarcoma, it is recommended to make an appointment with your doctor to be properly diagnosed.
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 102
  • Start Date: October 26, 2020
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 24
  • Start Date: September 23, 2019
A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients With Recurrent Malignant Glioma